Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen Pens Pharmacogenomics Deal With J&J Company to Predict Drug Response

NEW YORK, Jan. 11 (GenomeWeb News) - Perlegen Sciences will genotype patients for Johnson & Johnson Pharmaceutical Research and Development to find genetic markers indicating response to an undisclosed drug, the company said today.


Under the agreement, Perlegen will determine SNPs in several hundred patients and correlate them with therapeutic response to the drug. The aim is to predict the patient population that responds best to the agent.


The two parties did not disclose the terms of the collaboration. J&JPRD is a Johnson & Johnson company.